The University of Pennsylvania and drug company Novartis have joined forces to commercialize a new cancer-fighting approach that has proven promising in preliminary trials.
The alliance seeks to build on the recent results of an experimental treatment that trains a person’s immune system to kill cancer cells. Scientists at the university announced last year significant results in several patients with advanced chronic lymphocytic leukemia who were treated using the new technique, including two who went into complete remission.
Original source: The New York Times
Read the full story
here.